Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys $49,338.24 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor acquired 22,026 shares of the company’s stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Perspective Therapeutics Trading Up 4.6 %

Shares of Perspective Therapeutics stock opened at $2.05 on Thursday. The business’s 50 day moving average price is $2.85 and its 200 day moving average price is $6.07. Perspective Therapeutics, Inc. has a one year low of $1.90 and a one year high of $19.05.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CATX. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Monday. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.44.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC acquired a new stake in Perspective Therapeutics during the third quarter worth about $137,000. Charles Schwab Investment Management Inc. grew its stake in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after buying an additional 298,778 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after buying an additional 1,672 shares during the last quarter. FMR LLC raised its position in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after acquiring an additional 44,174 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.